Results 51 to 60 of about 5,421 (159)

Comparative Neurotoxicity of Polymyxin B and Colistin in Patients With Cancer

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 10, October 2026.
ABSTRACT Background The polymyxins, polymyxin B and colistin, are last‐line options for the treatment of infections caused by drug‐resistant gram‐negative organisms. The comparative neurotoxicity of these agents using contemporary dosing is poorly understood.
Samuel L. Aitken, Emily R. Aboujaoude, Jovan Borjan, Frank P. Tverdek   +3 more
wiley   +1 more source

Zwitterionic Penicillin‐Derived Sulfone Inhibitor for Combating β‐Lactamase‐Mediated Antibiotic Resistance

ChemMedChem, Volume 21, Issue 9, 14 May 2026.
Combining enhanced permeability strategies with (2‐pyridyl)methylene substitution in the sulbactam scaffold led to a novel β‐lactamase inhibitor to combat β‐lactamase‐mediated resistance to β‐lactam antibiotics. The studies presented highlight the potential of compound 3 as a next‐generation β‐lactamase inhibitor for combating infections caused by ...
Diana Rodríguez, Emilio Lence, Juan C. Vázquez‐Ucha, Alejandro Beceiro, Concepción González‐Bello   +4 more
wiley   +1 more source

Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects

, 2019
Sulbactam-durlobactam is being developed for the treatment of infections caused by , including those caused by multidrug- and carbapenem-resistant isolates.
Mamikonyan, Grigor, Preston, Richard A, Isaacs, Robin, Stone, Emily, O'Donnell, John   +4 more
core   +1 more source

Microbial Etiology and Antimicrobial Resistance in Pneumonia Among Hospitalized Patients in Kazakhstan: A Systematic Review and Single‐Arm Meta‐Analysis of Prevalence Data

Health Science Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background and Aims Pneumonia is an inflammatory condition of the lower respiratory tract, commonly caused by infection and associated with substantial morbidity and healthcare utilization. The burden of pneumonia on healthcare is exacerbated by limited data on pathogenic causes and associated antimicrobial resistance (AMR). Here, we conducted
Radmir Sarsenov, Maxim Solomadin, Alyona Lavrinenko, Vyacheslav Beloussov, Vitaliy Strochkov, Shynggys Orkara, Nurlan Sandybayev, Sergey Yegorov   +7 more
wiley   +1 more source

A Review of β‐Lactamase Inhibitors in Clinical Use and Development: Mechanisms, Spectrum, and Therapeutic Applications

International Journal of Microbiology, Volume 2026, Issue 1, 2026.
β‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β‐lactamase enzymes.
Mohammad Javad Roustaye Gourabi, Anita Nikoo, Bita Khanbabaei, Masoud Kargar, Amirhossein Fayyazi, Seyyed Mohammad Javad Mousavi, Amirhossein Aghdaee, Ali Hashemi, Javad Yasbolaghi Sharahi, Swaran J. S. Flora   +9 more
wiley   +1 more source

Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review

, 2022
A. baumannii is a frequent cause of difficult-to-treat healthcare-associated infections. The use of a novel beta-lactamase inhibitor, durlobactam, has been proposed against multidrug-resistant A. baumannii.
Francesco Schiavone, Petrosillo, Nicola, Fabrizio Taglietti, Granata, Guido, Nicola Petrosillo, Taglietti, Fabrizio, Schiavone, Francesco, Guido Granata   +7 more
core   +1 more source

Abstract Supplement

Pulmonary Medicine, Volume 2026, Issue 1, 2026.
 
Marzia Folegani, Semonti Nandi
wiley   +1 more source

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

Protein Spatial Structure Meets Artificial Intelligence: Revolutionizing Drug Synergy–Antagonism in Precision Medicine

Advanced Science, Volume 12, Issue 33, September 4, 2025.
This review comprehensively examines the applications of protein three‐dimensional structures and artificial intelligence in investigating drug synergistic and antagonistic effects. The research findings provide compelling evidence for the precision treatment of cancer and metabolic diseases, thereby promoting the development of personalized medicine ...
Anqi Lin, Chang Che, Aimin Jiang, Chang Qi, Antonino Glaviano, Zhijie Zhao, Zhirou Zhang, Zaoqu Liu, Ziyao Zhou, Quan Cheng, Shuofeng Yuan, Peng Luo   +11 more
wiley   +1 more source

Case Commentary: When susceptibility is not enough in recurrent Burkholderia cenocepacia infection

Antimicrobial Agents and Chemotherapy
In this issue, B. Gaglani, T. M. Andermann, C. Wate, J. Oldan, et al. (Antimicrob Agents Chemother 70:e01542-25, 2026, https://doi.org/10.1128/aac.01542-25) describe a recurrent Burkholderia cenocepacia infection successfully treated with cefiderocol ...
Simone Giuliano, Paolo Gaibani, Carlo Tascini   +2 more
doaj   +1 more source